Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile
Steven Artandi, MD, PhD

@scidirector

Stanford University medical oncologist and cancer scientist, and Director of the Stanford Cancer Institute. Follows and retweets are not endorsements.

ID: 1063242174408486912

linkhttp://cancer.stanford.edu calendar_today16-11-2018 01:27:43

1,1K Tweet

3,3K Followers

1,1K Following

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member Quynh Thu Le & colleagues found gold-siRNA supraclusters enhance tumor response to #StereotacticRadiotherapy by combining radiosensitization with #immunecheckpoint silencing. They promote immune activation & reduce immunosuppressive cells.

SCI member <a href="/Qle_stanford/">Quynh Thu Le</a> &amp; colleagues found gold-siRNA supraclusters enhance tumor response to #StereotacticRadiotherapy by combining radiosensitization with #immunecheckpoint silencing. They promote immune activation &amp; reduce immunosuppressive cells.
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member Ruijiang Li & team developed an AI model with visual & language data. Trained on 50M images and 1B pathology texts, it outperformed traditional methods in predicting cancer, identifying immunotherapy candidates, & spotting recurrence risks. go.nature.com/4afTaz5

SCI member Ruijiang Li &amp; team developed an AI model with visual &amp; language data. Trained on 50M images and 1B pathology texts, it outperformed traditional methods in predicting cancer, identifying immunotherapy candidates, &amp; spotting recurrence risks. go.nature.com/4afTaz5
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member James Zou & others have found 776 genomic alterations linked to survival outcomes across 20 cancer types with specific immunotherapies, chemotherapies, or targeted therapies. go.nature.com/4gPP7vQ #PrecisionOncology

SCI member James Zou &amp; others have found 776 genomic alterations linked to survival outcomes across 20 cancer types with specific immunotherapies, chemotherapies, or targeted therapies. go.nature.com/4gPP7vQ #PrecisionOncology
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

Please join SCI leader Quynh Thu Le and colleagues at the #AACRradiation25 Conference on Translating Targeted Therapies in Combination with Radiotherapy (January 26-29). bit.ly/4gWCIGM AACR @SJD956 Max Diehn, MD/PhD

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

Many tumors need more copper than healthy cells to grow. SCI member Jianghong Rao & others have developed a novel method to remove copper from tumor cells, effectively killing them. bit.ly/40Ao4PJ

Many tumors need more copper than healthy cells to grow. SCI member Jianghong Rao &amp; others have developed a novel method to remove copper from tumor cells, effectively killing them. bit.ly/40Ao4PJ
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member John Leppert & others found a potential link between certain #pesticides and increased prostate cancer incidence and mortality. bit.ly/4akVlkS John Leppert

SCI member John Leppert &amp; others found a potential link between certain #pesticides and increased prostate cancer incidence and mortality. bit.ly/4akVlkS <a href="/johnleppert/">John Leppert</a>
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member Christina Curtis & others found #BreastCancer spans three genomic archetypes: ER+ high-risk tumors with complex amplifications (ecDNA), HRD-like TNBC, and stable ER+ typical-risk tumors. These suggest new treatment targets, like PARP inhibitors. go.nature.com/4jpOyL2

SCI member <a href="/cncurtis/">Christina Curtis</a> &amp; others found #BreastCancer spans three genomic archetypes: ER+ high-risk tumors with complex amplifications (ecDNA), HRD-like TNBC, and stable ER+ typical-risk tumors. These suggest new treatment targets, like PARP inhibitors. go.nature.com/4jpOyL2
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

The Stanford Cancer Institute is continually building on its rich history of innovation and excellence to redefine the limits of what’s possible in cancer care.

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

The field of oncology has been completely transformed from where it was 15 years ago — it’s almost like science fiction now.

The field of oncology has been completely transformed from where it was 15 years ago — it’s almost like science fiction now.
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member Dimitrios Colevas & others found VK-2019 demonstrated an acceptable safety profile, achieved micromolar plasma concentrations, and showed on-target biological activity in tumors from patients with advanced EBV-positive #NasopharyngealCarcinoma. bit.ly/40Q2838

SCI member Dimitrios Colevas &amp; others found VK-2019 demonstrated an acceptable safety profile, achieved micromolar plasma concentrations, and showed on-target biological activity in tumors from patients with advanced EBV-positive #NasopharyngealCarcinoma. bit.ly/40Q2838
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

The microbiota modulates immune responses and influences cellular cancer therapies like hematopoietic cell transplantation and CAR T-cell therapy. SCI member Melody Smith, MD, MS explores the mechanisms behind these interactions and future research directions. bit.ly/4gCWbvb

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI members Dean Felsher, MD PhD, George Fisher & others found that 3 gastrointestinal #adenocarcinomas possess substantially different OS that appears differentially associated with HER2 status, mutp53, mutKRAS and MYC amplification. bit.ly/3CBLniU #GI25

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

SCI member John Leppert & others found that overtreatment of low-risk #ProstateCancer with surgery or radiotherapy < while overtreatment of men with limited life expectancy and intermediate- or high-risk disease >, mainly with radiotherapy. bit.ly/40Pbue6

Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

In a systematic review and meta-analysis SCI member Eleni Linos & team found that clinicians benefit from #AI assistance in #SkinCancer diagnosis regardless of their experience level. go.nature.com/3CKdcp7 Eleni Linos

In a systematic review and meta-analysis SCI member Eleni Linos &amp; team found that clinicians benefit from #AI assistance in #SkinCancer diagnosis regardless of their experience level. go.nature.com/3CKdcp7 <a href="/linos_eleni/">Eleni Linos</a>
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

Connect with me on LinkedIn for insights on our achievements, events, and gatherings at the Stanford Cancer Institute. bit.ly/3QreAQG #StanfordCancer

Connect with me on LinkedIn for insights on our achievements, events, and gatherings at the Stanford Cancer Institute.
bit.ly/3QreAQG
#StanfordCancer
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

I'm now on BlueSky! I look forward to continuing the conversation on the latest Stanford #CancerResearch with you there. Join me: bit.ly/3EOEvPW #StanfordCancer

I'm now on BlueSky! I look forward to continuing the conversation on the latest Stanford #CancerResearch with you there. Join me: bit.ly/3EOEvPW
#StanfordCancer
Steven Artandi, MD, PhD (@scidirector) 's Twitter Profile Photo

Zhengyi Deng & others found excess weight and adult weight gain were associated with increased risk of #RenalCellCarcinoma (RCC), particularly ccRCC, whereas weight loss was associated with reduced risk. bit.ly/3GDPfl9